EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa

Maeve Bradley iD, Eoghan Donlon iD, Amy Gallagher, Federica Ruggieri, John Inocentes, Antonio Diaz Rua, Clodagh O'Keeffe, Tim Lynch, Conor Fearon, Richard A Walsh

Movement Disorders Clinical Practice · 2026

DOI: 10.1002/mdc3.70533 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Maeve Bradley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dublin Neurological Institute at the Mater Misercordiae University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents, Disruptive, Impulse Control, and Conduct Disorders, Levodopa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Impulse control disorders (ICDs) are most often associated with dopamine agonists and pulsatile dopamine replacement therapy such as oral levodopa and subcutaneous apomorphine. Intestinal levodopa–carbidopa gel may improve ICDs through rationalization of dopaminergic agents and/or a reduction of pulsatile dopaminergic stimulation, however the impact of subcutaneous foslevodopa/foscarbidopa (CSFLI) has not been reported to date. Cases We describe five men aged 50–68 with advanced Parkinson's disease (PD) and pre‐existing ICDs who were switched to CSFLI. Four of them were transitioned directly from subcutaneous apomorphine infusions with the hope of improving ICD symptoms. All experienced worsening or persistent ICD symptoms, predominantly hypersexuality, after switching to CSFLI with a mean time to peak ICD symptoms of 4.5 weeks (range 2–6).

Conclusions

CSFLI may exacerbate ICDs in susceptible individuals. Pre‐treatment screening and close monitoring are recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseAntiparkinson AgentsDisruptive, Impulse Control, and Conduct DisordersLevodopaDopamine AgonistsHumansMaleMiddle AgedDrug CombinationsCarbidopaApomorphine

Stichwörter der Autor:innen

Parkinson's diseasefoslevodopa/foscarbidopaimpulse control disorder

Substanzen

Antiparkinson AgentsLevodopaDrug CombinationsDopamine AgonistsCarbidopacarbidopa, levodopa drug combinationApomorphine

Autor:innen und Institutionen

  • Dublin Neurological Institute at the Mater Misercordiae University Hospital, Dublin, Ireland.
  • School of Medicine, University College Dublin, Dublin, Ireland.
  • Health Affairs and School of Medicine, University College Dublin, Dublin, Ireland.

ORCID-Profile: Maeve Bradley, Eoghan Donlon

Zitieren

APA

Bradley, M., Donlon, E., Gallagher, A., Ruggieri, F., Inocentes, J., Rua, A. D., O'Keeffe, C., Lynch, T., Fearon, C., & Walsh, R. A. (2026). Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70533

Vancouver

Bradley M, Donlon E, Gallagher A, Ruggieri F, Inocentes J, Rua AD, et al. Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70533

BibTeX
@article{Bradley2026,
  author = {Bradley, Maeve and Donlon, Eoghan and Gallagher, Amy and Ruggieri, Federica and Inocentes, John and Rua, Antonio Diaz and O'Keeffe, Clodagh and Lynch, Tim and Fearon, Conor and Walsh, Richard A},
  title = {Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  doi = {10.1002/mdc3.70533}
}
Kostenlos starten →